FYB Formycon AG

15.36USD14.00 EUR · XETRA-3.45%Mkt Cap: 271.37M USDP/E: —

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular …

Key Statistics

Company
Market Cap271.37M USD
Enterprise Value223.91M USD
Revenue (TTM)67.17M USD
Gross Profit3.92M USD
Net Income (TTM)-70.96M USD
Revenue/Share3.80 USD
Last Price15.36 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees196
CountryDE
SectorHealthcare
IndustryBiotechnology
ISINDE000A1EWVY8
Valuation
P/E (Trailing)—
P/E (Forward)11.81
PEG—
EV/EBITDA21.70
EV/Revenue3.33
P/S4.04
P/B0.64
EPS (TTM)-1.62 USD
EPS (Forward)1.30 USD
52W Range
14.923% of range29.56
52W High29.56 USD
52W Low14.92 USD
Profitability
Gross Margin8.04%
Oper. Margin-24.25%
EBITDA Margin15.36%
Profit Margin-145.46%
ROE-16.21%
ROA-8.75%
ROIC-6.42%
ROCE-4.45%
Growth
Revenue Growth242.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF11.83M USD
CapEx (TTM)60.20M USD
FCF Margin-49.34%
FCF Yield-12.21%
Net Debt-47.46M USD
Net Debt/EBITDA-4.60
Net Debt/FCF—
Balance Sheet
Debt/Equity0.02
Current Ratio2.04
Quick Ratio1.42
Book Value/Sh23.93 USD
Cash/Share3.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)44.05 USD
Upside (mean)+186.9%
Target Range29.61 USD – 55.94 USD
29.61+186.9% to mean55.94
# Analysts6
Ownership
Shares Out.17.67M
Float—
Insiders30.41%
Institutions31.26%
Technical
SMA 5020.29 (-24.3%)
SMA 20021.08 (-27.2%)
Beta0.67
S&P 52W Chg12.00%
Avg Vol (30d)9.85K
Avg Vol (10d)19.45K
Technical Indicators
RSI (14)27.9
MACD-1.2447
MACD Signal-1.0871
MACD Hist.-0.1576
BB Upper22.99 USD
BB Middle18.22 USD
BB Lower13.44 USD
BB Width52.42%
ATR (14)0.8532 USD
Vol Ratio (20d)1.59x

About Formycon (ETR: FYB)

›

Formycon (ETR: FYB) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 196 employees.

The shares were at 14.00 EUR on 19 November 2026, down 39.8% over 52 weeks. Its 52-week range is 13.60 EUR to 26.95 EUR: the price is 48.1% below the high and 2.9% above the low.

Its market capitalisation is 247.42M EUR.

Formycon reports return on equity of -16.2%, an operating margin of -24.3% and revenue up 242.5% year over year.

It holds more cash than debt, a net cash position of 43.27M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 40.17 EUR is 186.9% above the current price. The next earnings report is expected on 25 March 2027.